Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/31875
Title: Real-world clinical outcomes and cost estimates of metastatic castration-resistant prostate cancer treatment: does sequencing of taxanes and androgen receptor-targeted agents matter?
Austin Authors: Pereira-Salgado, Amanda;Anton, Angelyn;Franchini, Fanny;Mahar, Robert K;Kwan, Edmond M;Wong, Shirley;Shapiro, Julia;Weickhardt, Andrew J ;Azad, Arun A;Spain, Lavinia;Gunjur, Ashray ;Torres, Javier;Parente, Phillip;Parnis, Francis;Goh, Jeffrey;Steer, Christopher;Brown, Stephen;Gibbs, Peter;Tran, Ben;IJzerman, Maarten
Affiliation: Centre for Cancer Research and Centre for Health Policy, Faculty of Medicine, Dentistry and Health Sciences, the University of Melbourne, Melbourne, Australia.
Department of Medicine, School of Clinical Sciences, Monash University, Melbourne, Australia.
Western Health, Melbourne, Australia.
Alfred Health, Melbourne, Australia.
Olivia Newton-John Cancer Wellness and Research Centre
Peter MacCallum Cancer Centre, Melbourne, Australia.
Department of Medicine, School of Clinical Sciences, Monash University, Melbourne, Australia.
Goulburn Valley Health, Shepparton, Australia.
Department of Medicine, School of Clinical Sciences, Monash University, Melbourne, Australia.
Adelaide Cancer Centre, Adelaide, Australia.
Royal Brisbane and Women's Hospital, Brisbane, Australia.
Border Medical Oncology, Albury Wodonga Regional Cancer Centre, Albury, Australia.
Ballarat Health Services, Ballarat, Australia.
Department of Personalised Medicine, Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia.
Issue Date: 2023
Date: 2022
Publication information: Expert Review of Pharmacoeconomics & Outcomes Research 2023; 23(2)
Abstract: Health economic outcomes of real-world treatment sequencing of androgen receptor-targeted agents (ARTA) and docetaxel (DOC) remain unclear.
URI: https://ahro.austin.org.au/austinjspui/handle/1/31875
DOI: 10.1080/14737167.2023.2161048
ORCID: 0000-0002-8459-7961
Journal: Expert Review of Pharmacoeconomics & Outcomes Research
Start page: 1
End page: 9
PubMed URL: 36541133
ISSN: 1744-8379
Type: Journal Article
Subjects: Health economics
metastatic castration-resistant prostate cancer
prostate cancer
time-to-treatment failure
treatment costs
treatment sequences
Appears in Collections:Journal articles

Show full item record

Page view(s)

26
checked on Apr 19, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.